Multiple case reports have described neurologic irAEs (irAEs-N), and previous research has found that up to 4.2% of cancer patients treated with anti-PD-1 therapy exhibited some level of neurologic dysfunction, with most occurring within 3 months of starting therapy [67]. The gene discussed is PDCD1; the disease is cancer.